An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects...

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2024 Mar 14

PMID 38483767

Authors

Gael Dos Santos

Raghavendra Devadiga

Chun Soo Kim

Joon Bang

Affiliations

Soon will be listed here.

Abstract

Introduction: Seasonal influenza is associated with substantial public health burden. The objective of this study was to assess the safety of inactivated quadrivalent seasonal influenza vaccine (IIV4, Fluarix Tetra, GSK, Belgium) in subjects aged ≥ 6 months in Korea.

Methods: This prospective, observational, non-comparative, multi-centre post-marketing surveillance study was conducted in Korea in subjects aged ≥ 3 years for 6 years (2014-2020) and extended to subjects aged 6-35 months for 4 years (2018-2022). Subjects received IIV4 in routine clinical practice according to local prescribing information. Adverse events (AEs) were recorded over 21 days post-vaccination.

Results: The group aged ≥ 3 years included 701 subjects (mean 31.97 years, range 3-86 years, 46.36% male), and the group aged 6-35 months included 687 subjects (mean 16.31 months, 47.02% male). In the group aged ≥ 3 years, 98 subjects (13.98%) reported 140 AEs, of which 42 events in 34 subjects (4.85%) were adverse reactions to vaccine (ARVs). Most of the ARVs were expected, mainly administration site reactions. There were seven mild unexpected ARVs. In the group aged 6-35 months, 248 AEs were reported in 149/687 subjects (21.69%). ARVs were reported in 25/687 subjects (3.64%, 29 events); one was considered unexpected. There were five serious AEs overall, none of which were considered related.

Conclusion: No safety concerns were found during this surveillance study of IIV4 in subjects aged ≥ 6 months in Korea. The findings of this study suggest IIV4 is safe and well tolerated for use in all age groups with a vaccine indication.

References

Yoo B, Kim C, Izu A, Arora A, Heijnen E . Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years. Infect Chemother. 2019; 50(4):301-310. PMC: 6312896. DOI: 10.3947/ic.2018.50.4.301. View

Dos Santos G, Shende V, Damaso S, Yeakey A . Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis. Adv Ther. 2019; 36(12):3340-3355. PMC: 6860958. DOI: 10.1007/s12325-019-01105-2. View

Iuliano A, Roguski K, Chang H, Muscatello D, Palekar R, Tempia S . Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2017; 391(10127):1285-1300. PMC: 5935243. DOI: 10.1016/S0140-6736(17)33293-2. View

Dos Santos G, Nguyen B, Damaso S, Godderis L, Martinez-Gomez X, Eckermann T . Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season. Drug Saf. 2019; 43(3):265-279. PMC: 7048703. DOI: 10.1007/s40264-019-00893-4. View

Paget J, Iuliano A, Taylor R, Simonsen L, Viboud C, Spreeuwenberg P . Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR project. Vaccine. 2022; 40(9):1361-1369. PMC: 8923032. DOI: 10.1016/j.vaccine.2021.11.080. View

de Lusignan S, Damaso S, Ferreira F, Byford R, McGee C, Pathirannehelage S . Brand-specific enhanced safety surveillance of GSK's Fluarix Tetra seasonal influenza vaccine in England: 2017/2018 season. Hum Vaccin Immunother. 2020; 16(8):1762-1771. PMC: 7482908. DOI: 10.1080/21645515.2019.1705112. View

Salamanca de la Cueva I, Cinconze E, Eckermann T, Nwoji U, Godderis L, Lu E . Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season. Drug Saf. 2021; 44(12):1375-1390. PMC: 8543775. DOI: 10.1007/s40264-021-01121-8. View

Kim H, Engel S, Neveu D, Thollot Y, Oster P, Yang K . Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra) in the Republic of Korea, 2014-2019. Infect Dis Ther. 2021; 10(1):399-409. PMC: 7954957. DOI: 10.1007/s40121-020-00393-4. View

Dos Santos G, Neumeier E, Bekkat-Berkani R . Influenza: Can we cope better with the unpredictable?. Hum Vaccin Immunother. 2015; 12(3):699-708. PMC: 4964641. DOI: 10.1080/21645515.2015.1086047. View

10.

Shin S, Kim C, Karkada N, Liu A, Jayadeva G, Han H . Post-marketing safety surveillance conducted in Korea (2008-2013) following the introduction of the rotavirus vaccine, RIX4414 (Rotarix™). Hum Vaccin Immunother. 2016; 12(10):2590-2594. PMC: 5084987. DOI: 10.1080/21645515.2016.1189046. View

11.

de Lusignan S, Correa A, Dos Santos G, Meyer N, Haguinet F, Webb R . Enhanced Safety Surveillance of Influenza Vaccines in General Practice, Winter 2015-16: Feasibility Study. JMIR Public Health Surveill. 2019; 5(4):e12016. PMC: 6913774. DOI: 10.2196/12016. View

12.

de Lusignan S, Ferreira F, Damaso S, Byford R, Pathirannehelage S, Yeakey A . Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card. Hum Vaccin Immunother. 2019; 15(5):1048-1059. PMC: 6605873. DOI: 10.1080/21645515.2019.1565258. View

13.

Ray R, Dos Santos G, Buck P, Claeys C, Matias G, Innis B . A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Hum Vaccin Immunother. 2017; 13(7):1640-1652. PMC: 5512791. DOI: 10.1080/21645515.2017.1313375. View

14.

Choe Y, Vidor E, Manson C . Post-Marketing Surveillance of Tetravalent Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus (DTaP-IPV) Vaccine in South Korea, 2009 to 2015. Infect Dis Ther. 2022; 11(4):1479-1492. PMC: 9334467. DOI: 10.1007/s40121-022-00650-8. View

15.

Choi W, Cowling B, Noh J, Song J, Wie S, Lee J . Disease burden of 2013-2014 seasonal influenza in adults in Korea. PLoS One. 2017; 12(3):e0172012. PMC: 5344334. DOI: 10.1371/journal.pone.0172012. View

16.

Dos Santos G, Wang H, Jindal P, Rybo M, Roul H, Pallem S . Brand-Specific Enhanced Safety Surveillance Study of GSK's Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season. Infect Dis Ther. 2021; 11(1):463-483. PMC: 8711683. DOI: 10.1007/s40121-021-00571-y. View

17.

Park H, Kim S, Song R, Chen J, Kim J, Devadiga R . A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea. J Korean Med Sci. 2019; 34(12):e105. PMC: 6439203. DOI: 10.3346/jkms.2019.34.e105. View

18.

Dos Santos G . Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives. Hum Vaccin Immunother. 2019; 15(11):2624-2636. PMC: 6930062. DOI: 10.1080/21645515.2019.1608745. View

19.

Hong K, Sohn S, Chun B . Estimating Influenza-associated Mortality in Korea: The 2009-2016 Seasons. J Prev Med Public Health. 2019; 52(5):308-315. PMC: 6780294. DOI: 10.3961/jpmph.19.156. View

20.

Kim H, Webster R, Webby R . Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral Immunol. 2018; 31(2):174-183. DOI: 10.1089/vim.2017.0141. View